We learned several months ago that the ATLAS trial of maintenance Avastin (bevacizumab) with either Tarceva (erlotinib) or placebo did not demonstrate a significant improvement in overall survival (OS) with Tarceva, despite the fact that it was associated with an improvement in progres

Dr. Mark Socinski, international leader in the field of lung cancer, from the University of North Carolina at Chapel Hill, gave a terrific presentation on timing and selection of treatment after the first line setting for advanced NSCLC. In addition to the podcast of his presentation itself, here now is the question and answer session that followed it.

The Q&A portion includes slides with the questions as well as some slides that illustrate key points. Below, you'll find the audio and video versions of the podcast, the figures, and also the transcript of the program.

I'm very pleased to offer the podcast materials for the recent webinar by Dr. Mark Socinski, medical oncologist and leader of the excellent Thoracic Oncology Program at the University of North Carolina, in Chapel Hill. He's been a long-time leader of the entire field of lung cancer for many years, and he's among the best at synthesizing new information into a cogent perspective.

Here is the audio and video versions of the podcast, along with the figures and transcript that go with the program.

[powerpress]

Dr.

Over the past several months the topic of so-called maintenance therapy in advanced NSCLC has been one of the most timely and controversy questions in lung cancer. We've had posts here covering a trial testing immediate vs.

Last week we discussed SATURN, the first of 2 recently presented trials testing the role of maintenance Tarceva (erlotinib) in advanced NSCLC patients. Today I will discuss the ATLAS trial, the last of the 4 major maintenance therapy trials (along with immediate versus delayed Taxotere (docetaxel) and maintenance Alimta (pemetrexed)).

With special thanks to Harvey and Bernice Janssen for providing support to make it possible, I'm pleased to post a new video presentation on the topic of Timing the Transition to Maintenance/Second Line Chemotherapy for Advanced NSCLC. We can expect new information to emerge in the coming months and years, but here is the current snapshot of what we know, along with a little describing what I think (noted as such), about this important topic today.

[powerpress]

For those accessing the audio only version (mp3), the accompanying figures are here, as well as a transcript: